Immune checkpoint inhibitors in the treatment and management of hepatocellular carcinoma-related adverse reactions
10.3760/cma.j.cn501113-20191010-00368
- VernacularTitle:免疫检查点抑制剂治疗肝细胞癌相关不良反应及管理
- Author:
Zhongchen LI
1
;
Zhenggang REN
Author Information
1. 复旦大学附属中山医院肝肿瘤内科 复旦大学肝癌研究所，上海 200032
- Keywords:
Hepatocellular carcinoma;
Immune checkpoint inhibitor;
Immune related adverse event
- From:
Chinese Journal of Hepatology
2021;29(6):600-603
- CountryChina
- Language:Chinese
-
Abstract:
The application of immune checkpoint inhibitors has significantly improved the immunotherapy effect of a variety of solid tumors. With the US Food and Drug Administration's approval of nivolumab and pembrolizumab as second-line treatments for hepatocellular carcinoma, the application of immune checkpoint inhibitors, especially in combination with other treatment methods, has become more and more widely used in hepatocellular carcinoma. Notably, these drugs play a therapeutic role in tumor immunosuppression; however, they can also stimulate related side effects caused by autoimmunity, so their side effects are very different from traditional chemotherapy and targeted drugs. Therefore, effective monitoring, detection and intervention of immune-related side effects are obligatory assurances for patients to attain clinical benefits.
